The currents swirling around the steep price increases on Mylan NV’s (NASDAQ:MYL) lifesaving EpiPen drug just got a little deeper for the company’s embattled CEO. When the company’s chief executive Heather Bresch testified before a congressional committee last week, it was claimed that Mylan’s profit on a $ 608 two-pack of the injectors was just $ 100. […]
Corporate News – The Cerbat Gem
Showing posts with label Profits. Show all posts
Showing posts with label Profits. Show all posts
Wednesday, January 25, 2017
Mylan Under Fire For Creative Accounting Of EpiPen Profits
Subscribe to:
Posts (Atom)